SOURCE-LINKED PREPARATION NOTES

Diluent, clarity & fragility

Product labeling, laboratory methods and community reports are identified separately. These findings do not establish a universal injectable preparation.

Visible-change discard rule

For products intended to form clear solutions, do not use or attempt to salvage unexpected persistent cloudiness, strings, flakes, precipitate, thickening or gel. Intentionally formulated suspensions, such as specific triptorelin depot products, have their own instructions. Adding liquid, warming, or vigorous mixing cannot establish identity, sterility, potency, or uniform concentration.

PROFILE 01

Tesamorelin

Product-specific preparation context

Source-linked preparation review

Product / research formulation context

EGRIFTA SV specifies its supplied Sterile Water for Injection; EGRIFTA WR specifies its supplied Bacteriostatic Water for Injection. Their preparation and post-reconstitution storage rules differ.

Other approaches discussed

The labeled examples below remain product-specific. Neither product instruction validates a generic 10 mg vial, a blend, acid addition or another solvent substitution.

Evidence context: Product / laboratory / report distinctions apply
Cloudiness / gel signal: Distinct labeled diluents; community clouding reports separate

Details to verify for the actual product

Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.

Evidence boundary

Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.

Sources

Product label: EGRIFTA SV FDA label

Product label: EGRIFTA WR FDA label

Reviewed October 20, 2026

PROFILE 02

Kisspeptin

Product-specific preparation context

Source-linked preparation review

Product / research formulation context

Kisspeptin-10 and kisspeptin-54 are different materials. Supplier water-solubility data apply to a particular peptide/product; community accounts include incomplete dissolution and gel-like material.

Other approaches discussed

Water, PBS and acidified approaches are discussed with conflicting outcomes. No universally validated solvent, concentration or prevention ratio was identified.

Evidence context: Product / laboratory / report distinctions apply
Cloudiness / gel signal: Recurrent community clouding / gel-like reports

Details to verify for the actual product

Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.

Evidence boundary

Sources

Laboratory supplier or secondary reference — product-specific: Tocris human kisspeptin-10

Community/vendor report — unvalidated: Kisspeptin gelling discussion

Reviewed October 20, 2026

PROFILE 03

AOD-9604

Product-specific preparation context

Source-linked preparation review

Product / research formulation context

Community accounts describe persistent clouding, incomplete dissolution and gel-like material after water-based preparation. The cause and frequency are not established by those reports.

Other approaches discussed

Water, buffers/PBS and acidified media appear in laboratory or commercial accounts. These alternatives do not establish an injectable correction or a universal acid requirement.

Evidence context: Product / laboratory / report distinctions apply
Cloudiness / gel signal: Recurrent community clouding / gel-like reports

Details to verify for the actual product

Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.

Evidence boundary

Sources

Laboratory supplier or secondary reference — product-specific: Cayman AOD-9604 acetate specifications

Community/vendor report — unvalidated: AOD-9604 clouding discussion

Reviewed October 20, 2026

PROFILE 04

KLOW

Product-specific preparation context

Source-linked preparation review

Product / research formulation context

The 80 mg blend combines four ingredients including GHK-Cu. The finished mixture requires its own compatibility evidence; separate ingredient methods do not validate it.

Other approaches discussed

Vendor water/PBS/acid opinions do not establish a universal formula or beyond-use period. Appearance cannot verify ingredient identity, copper coordination or sterility.

Evidence context: Product / laboratory / report distinctions apply
Cloudiness / gel signal: Copper-containing four-component compatibility unresolved

Details to verify for the actual product

Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.

Evidence boundary

Sources

Research study — applies to its stated conditions: GHK-Cu dermal preformulation study

Laboratory supplier or secondary reference — product-specific: KLOW supplier handling page

Reviewed October 20, 2026

PROFILE 05

GLOW

Product-specific preparation context

Source-linked preparation review

Product / research formulation context

The 70 mg same-vial blend contains a copper complex together with other peptides. Evidence for separately prepared ingredients does not establish stability or compatibility of the finished mixture.

Other approaches discussed

Vendor water/PBS and chelator warnings are product-specific. Adding acid, PBS or another ingredient is not a validated way to rescue a cloudy blend.

Evidence context: Product / laboratory / report distinctions apply
Cloudiness / gel signal: Copper-containing finished-blend compatibility unresolved

Details to verify for the actual product

Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.

Evidence boundary

Sources

Research study — applies to its stated conditions: GHK-Cu dermal preformulation study

Laboratory supplier or secondary reference — product-specific: GLOW supplier handling page

Reviewed October 20, 2026

PROFILE 06

ARA-290

Product-specific preparation context

Recurrent reports

Product / research formulation context

PBS is reported for unbuffered research powder. Published animal methods used PBS. Human trial preparations were formulation-specific; one protocol used a vial already containing phosphate buffer (pH 6.5), sucrose and mannitol, reconstituted with sterile Water for Injection.

Other approaches discussed

Community reports describe PBS alone, PBS with bacteriostatic water, and water added to already-buffered vials. These are different preparations. No universal PBS/BAC ratio or comparative anti-gelling method was validated in the sources reviewed on October 20, 2026.

Evidence context: Conflicting reports; buffer already in the vial may matter
Cloudiness / gel signal: Recurrent clouding / incomplete dissolution; gel-like material also reported

Details to verify for the actual product

Check the actual vial's buffer and excipient content, salt form, concentration, pH and product instructions. These may contribute to differing reports; the cause and incidence of gelling have not been established by a comparative study.

Evidence boundary

PBS use in a study does not prove every vial requires added PBS, and a prebuffered trial vial does not validate water alone for unbuffered powder. Laboratory PBS is not automatically an injectable-grade diluent. Adding BAC changes buffer and preservative concentrations; clarity does not establish sterility, stability or suitability. Do not attempt to rescue cloudy or gelled material.

Sources

Human trial protocol, July 6, 2017 — section 9.1, prebuffered vial

Animal study, 2014 — PBS in treatment methods

Community report — buffered versus unbuffered vials (anecdotal)

Community report — cloudiness after BAC water (anecdotal)

Community discussion — PBS/BAC conflicts and gel-like reports (anecdotal)

COMPLETED REVIEW

Reviewed compound profiles

All 67 library entries were screened. These 59 entries received updated or clarified preparation notes; existing ARA-290 corrections and seven entries were retained. Open a compound in the Research Index for its findings and source links.

PE-22-285-Amino-1MQAdamaxAHK-CuAOD-9604AviptadilCagrilintideCagriSemaCerebrolysinCJC-1295CJC-1295 + IpamorelinDihexaElamipretideEloralintideEpitalonGHK-CuGHRP-2GHRP-6GLOWGlutathioneGonadorelinHexarelinHGH Fragment 176-191HumaninIGF-1 LR3IpamorelinKisspeptinKLOWKPVLL-37Mechano Growth FactorMelanotan IIMethylene BlueMod GRF(1-29)MOTS-cNAD+OxytocinPramlintideRetatrutideSelankSelank + SemaxSemaglutideSemaxSermorelinSLU-PP-332SomatropinTB-500TesamorelinTesamorelin + IpamorelinThymosin Alpha-1Thymosin Beta-4TriptorelinWolverineAfamelanotideBPC-157DSIPMazdutidePemvidutidePinealonSurvodutide

How this appears across the site

Flagged compound pages show the same six fields: product or research context, alternatives discussed, evidence context, visible-change signal, product details to verify, and an evidence boundary. Conditional arithmetic examples do not establish a solvent recipe.